Caring for the breast cancer survivor's health and wellbeing

World Journal of Clinical Oncology

Volumn 5, Issue 4, 2014, Pages 693-704

  Casey, Petra M ^a   Faubion, Stephanie S ^a   MacLaughlin, Kathy L ^a   Long, Margaret E ^a   Pruthi, Sandhya ^b  

^a MAYO CLINIC   (United States)

^b Breast Clinic Minnesota   (United States)

Author keywords

Breast cancer; Breast cancer recurrence; Breast cancer surveillance; Contraception; Osteopenia; Osteoporosis; Sexual health; Vasomotor symptoms; Vulvovaginal atrophy

Indexed keywords

EID: 84925372053     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i4.693     Document Type: Review

References (97)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29 [PMID: 22237781 DOI: 10.3322/caac.20138]
2. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784-1792 [PMID: 16251534 DOI: 10.1056/NEJMoa050518]
3. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-241 [PMID: 22700443 DOI: 10.3322/caac.21149]
4. Thompson CA, Stan DL, Solberg Nes L, Jenkins SM, Lackore KA, Pruthi S. Breast cancer survivors' self-reported needs and preferences of survivorship care. Breast J 2013; 20: 107-109 [PMID: 24262015 DOI: 10.1111/tbj.12221]
5. Hewitt M, Greenfield S, Stovall E, editors. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: National Academics Press, 2006
6. Loblaw DA, Prestrud AA, Somerfield MR, Oliver TK, Brouwers MC, Nam RK, Lyman GH, Basch E. American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol 2012; 30: 3136-3140 [PMID: 22778311 DOI: 10.1200/jco.2012.42.0489]
7. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA 1994; 271: 1593-1597 [PMID: 7848404]
8. Barnett GC, Shah M, Redman K, Easton DF, Ponder BA, Pharoah PD. Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol 2008; 26: 3310-3316 [PMID: 18612147 DOI: 10.1200/jco.2006.10.3168]
9. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57: 75-89 [PMID: 17392385]
10. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23: 619-629 [PMID: 15545664 DOI: 10.1200/jco.2005.09.121]
11. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805-816 [PMID: 23219286 DOI: 10.1016/s0140-6736(12)61963-1]
12. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010; 28: 4120-4128 [PMID: 20585090 DOI: 10.1200/jco.2009.25.9655]
13. Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, Sternfeld B, Matthews K. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women' s health across the nation. Am J Public Health 2006; 96: 1226-1235 [PMID: 16735636 DOI: 10.2105/ajph.2005.066936]
14. Freeman EW, Sammel MD, Lin H, Liu Z, Gracia CR. Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol 2011; 117: 1095-1104 [PMID: 21508748 DOI: 10.1097/AOG.0b013e318214f0de]
15. Rödström K, Bengtsson C, Lissner L, Milsom I, Sundh V, Björkelund C. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause 2002; 9: 156-161 [PMID: 11973438]
16. Files JA, Ko MG, Pruthi S. Managing aromatase inhibitors in breast cancer survivors: not just for oncologists. Mayo Clin Proc 2010; 85: 560-566; quiz 566 [PMID: 20511486 DOI: 10.4065/mcp.2010.0137]
17. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012; 19: 257-271 [PMID: 22367731 DOI: 10.1097/gme.0b013e31824b970a]
18. Prior JC, Hitchcock CL. Progesterone for hot flush and night sweat treatment-effectiveness for severe vasomotor symptoms and lack of withdrawal rebound. Gynecol Endocrinol 2012; 28 Suppl 2: 7-11 [PMID: 22849758 DOI: 10.3109/09513 590.2012.705390]
19. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet 2004; 363: 453-455 [PMID: 14962527 DOI: 10.1016/s0140-6736(04)15493-7]
20. Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE, Peralta O, Arriagada R, Holmqvist M, Maenpaa J. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008; 100: 475-482 [PMID: 18364505 DOI: 10.1093/jnci/djn058]
21. Batur P, Blixen CE, Moore HC, Thacker HL, Xu M. Menopausal hormone therapy (HT) in patients with breast cancer. Maturitas 2006; 53: 123-132 [PMID: 16368466 DOI: 10.1016/j.maturitas.2005.03.004]
22. Santen RJ. Menopausal hormone therapy and breast cancer. J Steroid Biochem Mol Biol 2014; 142: 52-61 [PMID: 23871991 DOI: 10.1016/j.jsbmb.2013.06.010]
23. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013; 310: 1353-1368 [PMID: 24084921 DOI: 10.1001/jama.2013.278040]
24. Haskell SG, Bean-Mayberry B, Gordon K. Discontinuing postmenopausal hormone therapy: an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms? Menopause 2009; 16: 494-499 [PMID: 19182695 DOI: 10.1097/gme.0b013e31818fbff5]
25. Ockene JK, Barad DH, Cochrane BB, Larson JC, Gass M, Wassertheil-Smoller S, Manson JE, Barnabei VM, Lane DS, Brzyski RG, Rosal MC, Wylie-Rosett J, Hays J. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005; 294: 183-193 [PMID: 16014592 DOI: 10.1001/jama.294.2.183]
26. de Villiers TJ, Gass ML, Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees M. Global consensus statement on menopausal hormone therapy. Climacteric 2013; 16: 203-204 [PMID: 23488524 DOI: 10.3109/13697137.2013.771520]
27. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, Nicolaidis C, Walker M, Humphrey L. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006; 295: 2057-2071 [PMID: 16670414 DOI: 10.1001/jama.295.17.2057]
28. Sternfeld B, Guthrie KA, Ensrud KE, LaCroix AZ, Larson JC, Dunn AL, Anderson GL, Seguin RA, Carpenter JS, Newton KM, Reed SD, Freeman EW, Cohen LS, Joffe H, Roberts M, Caan BJ. Efficacy of exercise for menopausal symptoms: a randomized controlled trial. Menopause 2014; 21: 330-338 [PMID: 23899828 DOI: 10.1097/GME.0b013e31829e4089]
29. Borud E, White A. A review of acupuncture for menopausal problems. Maturitas 2010; 66: 131-134 [PMID: 20060667 DOI: 10.1016/j.maturitas.2009.12.010]
30. Hall E, Frey BN, Soares CN. Non-hormonal treatment strategies for vasomotor symptoms: a critical review. Drugs 2011; 71: 287-304 [PMID: 21319867 DOI: 10.2165/11585360-0 00000000-00000]
31. Richardson MK. Alternatives to hormone therapy for hot flashes: many choices but science is lacking. Menopause 2013; 20: 980-982 [PMID: 23839221 DOI: 10.1097/GME.0b013e3182982436]
32. Rada G, Capurro D, Pantoja T, Corbalán J, Moreno G, Letelier LM, Vera C. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2010; (9): CD004923 [PMID: 20824841 DOI: 10.1002/14651858.CD004923.pub2]
33. Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, Sweeney TJ, Banerjee TK, Flynn PJ. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double- blind placebo-controlled trial. Lancet 2005; 366: 818-824 [PMID: 16139656 DOI: 10.1016/s0140-6736(05)67215-7]
34. Loprinzi CL, Kugler JW, Barton DL, Dueck AC, Tschetter LK, Nelimark RA, Balcueva EP, Burger KN, Novotny PJ, Carlson MD, Duane SF, Corso SW, Johnson DB, Jaslowski AJ. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol 2007; 25: 308-312 [PMID: 17146104 DOI: 10.1200/jco.2006.07.5390]
35. Simon J. Safety and Efficacy of Low-dose Mesylate Salt of Paroxetine (LDMP) for the Treatment of Vasomotor Symptoms; Abstract. The North American Menopause Society 24th Annual Meeting; 2013 Oct 9-12; Dallas, TX
36. Pinkerton JV, Archer DF, Guico-Pabia CJ, Hwang E, Cheng RF. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial. Menopause 2013; 20: 38-46 [PMID: 23266839 DOI: 10.1097/GME.0b013e318274699f]
37. Baldwin DS, Palazzo MC, Masdrakis VG. Reduced treatment- emergent sexual dysfunction as a potential target in the development of new antidepressants. Depress Res Treat 2013; 2013: 256841 [PMID: 23431429 DOI: 10.1155/2013/256841]
38. Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev 2013; 5: CD003382 [PMID: 23728643 DOI: 10.1002/14651858.CD003382.pub3]
39. Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 2013; 31: 176-180 [PMID: 23091108 DOI: 10.1200/jco.2012.44.6625]
40. Haest K, Kumar A, Van Calster B, Leunen K, Smeets A, Amant F, Berteloot P, Wildiers H, Paridaens R, Van Limbergen E, Weltens C, Janssen H, Peeters S, Menten J, Vergote I, Morlion B, Verhaeghe J, Christiaens MR, Neven P. Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up. Ann Oncol 2012; 23: 1449-1454 [PMID: 22039079 DOI: 10.1093/annonc/mdr478]
41. Guttuso T. Stellate ganglion block for treating hot flashes: a viable treatment option or sham procedure? Maturitas 2013; 76: 221-224 [PMID: 24021996 DOI: 10.1016/j.maturitas.2013.08.001]
42. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010; 85: 87-94 [PMID: 20042564 DOI: 10.4065/mcp.2009.0413]
43. Krychman ML, Katz A. Breast cancer and sexuality: multimodal treatment options. J Sex Med 2012; 9: 5-13; quiz 14-15 [PMID: 22151953 DOI: 10.1111/j.1743-6109.2011.02566.x]
44. Pruthi S, Simon JA, Early AP. Current overview of the management of urogenital atrophy in women with breast cancer. Breast J 2011; 17: 403-408 [PMID: 21645165 DOI: 10.1111/j.1524-4741.2011.01089.x]
45. Sinha A, Ewies AA. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric 2013; 16: 305-312 [PMID: 23215675 DOI: 10.3109/13697137.2 012.756466]
46. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013; 20: 888-902; quiz 903-904 [PMID: 23985562 DOI: 10.1097/GME.0b013e3182a122c2]
47. Capobianco G, Donolo E, Borghero G, Dessole F, Cherchi PL, Dessole S. Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. Arch Gynecol Obstet 2012; 285: 397-403 [PMID: 21706345 DOI: 10.1007/s00404-011-1955-1]
48. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010; 11: 1135-1141 [PMID: 21087898 DOI: 10.1016/s1470-2045(10)70257-6]
49. Moegele M, Buchholz S, Seitz S, Ortmann O. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Arch Gynecol Obstet 2012; 285: 1397-1402 [PMID: 22212649 DOI: 10.1007/s00404-011-2181-6]
50. Witherby S, Johnson J, Demers L, Mount S, Littenberg B, Maclean CD, Wood M, Muss H. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist 2011; 16: 424-431 [PMID: 21385795 DOI: 10.1634/theoncologist. 2010-0435]
51. Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Martel C, Balser J. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecol Endocrinol 2010; 26: 524-532 [PMID: 20459349 DOI: 10.3109/09513590903511547]
52. Buckner J. ClinicalTrials.gov Identifier: NCT01376349. Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms. Cited 2013-12-17. Available from: URL: http://clinicaltrials. gov/show/NCT01376349
53. Wurz GT, Soe LH, Degregorio MW Ospemifene, vulvovaginal atrophy, and breast cancer. Maturitas 2013 Jan 15; Epub ahead of print [PMID: 23332519 DOI: 10.1016/j.maturitas.2012.12.002]
54. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975-2010, based on November 2012 SEER data submission, posted to the SEER web site. Available from: URL: http://seer.cancer.gov/csr/1975-2010/
55. Su HI. Measuring ovarian function in young cancer survivors. Minerva Endocrinol 2010; 35: 259-270 [PMID: 21178920]
56. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr 1986; (1): 105-109 [PMID: 3534581]
57. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, Quinn G, Wallace WH, Oktay K. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31: 2500-2510 [PMID: 23715580 DOI: 10.1200/jco.2013.49.2678]
58. de Bree E, Makrigiannakis A, Askoxylakis J, Melissas J, Tsiftsis DD. Pregnancy after breast cancer. A comprehensive review. J Surg Oncol 2010; 101: 534-542 [PMID: 20401921 DOI: 10.1002/jso.21514]
59. Azim HA, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, De Mattos-Arruda L, Pistilli B, Pinto A, Jensen MB, Cordoba O, de Azambuja E, Goldhirsch A, Piccart MJ, Peccatori FA. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol 2013; 31: 73-79 [PMID: 23169515 DOI: 10.1200/jco.2012.44.2285]
60. Valachis A, Tsali L, Pesce LL, Polyzos NP, Dimitriadis C, Tsalis K, Mauri D. Safety of pregnancy after primary breast carcinoma in young women: a meta-analysis to overcome bias of healthy mother effect studies. Obstet Gynecol Surv 2010; 65: 786-793 [PMID: 21411023 DOI: 10.1097/OGX.0b013e31821285bf]
61. Leal SC, Stuart SR, Carvalho Hde A. Breast irradiation and lactation: a review. Expert Rev Anticancer Ther 2013; 13: 159-164 [PMID: 23406557 DOI: 10.1586/era.12.178]
62. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, Bernstein L, Malone KE, Ursin G, Strom BL, Norman SA, Wingo PA, Burkman RT, Berlin JA, Simon MS, Spirtas R, Weiss LK. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346: 2025-2032 [PMID: 12087137 DOI: 10.1056/NEJMoa013202]
63. Casey PM, Cerhan JR, Pruthi S. Oral contraceptive use and risk of breast cancer. Mayo Clin Proc 2008; 83: 86-90; quiz 90-91 [PMID: 18174010]
64. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727 [PMID: 8656904]
65. Association of Reproductive Health Professionals. Nonhormonal Contraceptive Methods. Section 1. Highly Effective Non-hormonal Methods Available in the US Male Sterilization, published July 2013. Cited 2013-12-17. Available from: URL: http://www.arhp.org/Publications-and- Resources/Quick-Reference-Guide-for-Clinicians/Nonhormonal- Choosing/male-sterilization
66. Association of Reproductive Health Professionals. Nonhormonal Contraceptive Methods. Female Sterilization, published July 2013. Cited 2013-12-17. Available from: URL: http://www.arhp.org/Publications-and-Resources/Quick- Reference-Guide-for-Clinicians/Non-hormonal-Choosing/female-sterilization
67. Conceptus Incorporated. Essure package insert, cited 2013-12-16. Available from: URL: http://www.essuremd. com/App-Themes/BaseTheme/PDFs/Link Essure IFU.pdf
68. Centers for Disease Control and Prevention (CDC). United States Medical Eligibility Criteria (US MEC) for Contraceptive Use, 2010. Cited 2013-12-16. Available from: URL: http://www.cdc.gov/reproductivehealth/unintendedpregnancy/usmec.htm
69. Trussell J. Contraceptive efficacy. In Contraceptive Technology. 18th edition. In: Hatcher R, Trussell J, Stewart F, Nelson A, Cates W, Guest F, Kowal D, edtiors. New York, NY: Ardent Media, Incorporated, 2007
70. Teva Women's Health Inc. ParaGard T 380A Intrauterine Copper Contraceptive package insert, updated June 2013. Cited 2013-12-16. Available from: URL: http://www.paragard. com/images/ParaGard-info.pdf
71. Bayer HealthCare Pharmaceuticals Inc. Mirena (levonorgestrel- releasing intrauterine system) package insert, updated February 2013. Cited 2013-12-16. Available from: URL: http://labeling.bayerhealthcare.com/html/products/pi/Mirena-PI.pdf
72. Bayer HealthCare Pharmaceuticals Inc. SKYLA (levonorgestrel- releasing intrauterine system) package insert, updated September 2013. Cited 2013-12-16. Available from: URL: http://labeling.bayerhealthcare.com/html/products/pi/Skyla-PI.pdf
73. Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 2011; 83: 211-217 [PMID: 21310281 DOI: 10.1016/j.contraception.2010.11.009]
74. Trinh XB, Tjalma WA, Makar AP, Buytaert G, Weyler J, van Dam PA. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril 2008; 90: 17-22 [PMID: 17706209 DOI: 10.1016/j.fertnstert.2007.05.033]
75. Milsom I. The levonorgestrel-releasing intrauterine system as an alternative to hysterectomy in peri-menopausal women. Contraception 2007; 75: S152-S154 [PMID: 17531608 DOI: 10.1016/j.contraception.2007.01.003]
76. Lukes AS, Moore KA, Muse KN, Gersten JK, Hecht BR, Edlund M, Richter HE, Eder SE, Attia GR, Patrick DL, Rubin A, Shangold GA. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol 2010; 116: 865-875 [PMID: 20859150 DOI: 10.1097/AOG.0b013e3181f20177]
77. Roy SN, Bhattacharya S. Benefits and risks of pharmacological agents used for the treatment of menorrhagia. Drug Saf 2004; 27: 75-90 [PMID: 14717620]
78. Merck & Co. Inc. NEXPLANON (etonogestrel implant) package insert, updated September 2013. Cited 2013-12-16. Available from: URL: http://www.merck.com/product/usa/pi-circulars/n/nexplanon/nexplanon-pi.pdf
79. Blumenfeld Z. Chemotherapy and fertility. Best Pract Res Clin Obstet Gynaecol 2012; 26: 379-390 [PMID: 22281514 DOI: 10.1016/j.bpobgyn.2011.11.008]
80. Di Cosimo S, Alimonti A, Ferretti G, Sperduti I, Carlini P, Papaldo P, Fabi A, Gelibter A, Ciccarese M, Giannarelli D, Mandalà M, Milella M, Ruggeri EM, Cognetti F. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol 2004; 15: 1065-1071 [PMID: 15205200 DOI: 10.1093/annonc/mdh266]
81. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. Cited 2013-12-16. Available from: URL: http://whqlibdoc.who.int/publications/2004/9241562668. pdf
82. Zhou L, Xiao B. Emergency contraception with Multiload Cu-375 SL IUD: a multicenter clinical trial. Contraception 2001; 64: 107-112 [PMID: 11704087]
83. Watson Pharma Inc. ELLA (ulipristal acetate tablet) package insert, updated April 2012. Cited 2013-12-17. Available from: URL: http://pi.actavis.com/data-stream.asp?product-group=1699&p=pi&language=E
84. Barr Pharmaceuticals Inc. Plan B One-Step (levonorgestrel) tablet package insert, updated August 2009. Cited 2013-12-17. Available from: URL: http://www.planbonestep. com/pdf/PlanBOneStepFullProductInformation.pdf
85. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1998; 352: 428-433 [PMID: 9708750]
86. Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, Sogor L, Blithe DL, Scherrer B, Mathe H, Jaspart A, Ulmann A, Gainer E. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet 2010; 375: 555-562 [PMID: 20116841 DOI: 10.1016/s0140-6736(10)60101-8]
87. Reid DM. Prevention of osteoporosis after breast cancer. Maturitas 2009; 64: 4-8 [PMID: 19709826 DOI: 10.1016/j.maturitas.2009.07.008]
88. Abdel-Razeq H, Awidi A. Bone health in breast cancer survivors. J Cancer Res Ther 2011; 7: 256-263 [PMID: 22044804 DOI: 10.4103/0973-1482.87006]
89. Aapro MS, Coleman RE. Bone health management in patients with breast cancer: current standards and emerging strategies. Breast 2012; 21: 8-19 [PMID: 21958673 DOI: 10.1016/j.breast.2011.08.138]
90. Peppone LJ, Mustian KM, Rosier RN, Carroll JK, Purnell JQ, Janelsins MC, Morrow GR, Mohile SG. Bone health issues in breast cancer survivors: a Medicare Current Beneficiary Survey (MCBS) study. Support Care Cancer 2014; 22: 245-251 [PMID: 24043289 DOI: 10.1007/s00520-013-1967-4]
91. Michaud LB, Goodin S. Cancer-treatment-induced bone loss, part 1. Am J Health Syst Pharm 2006; 63: 419-430 [PMID: 16484516 DOI: 10.2146/ajhp050045.p1]
92. Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008; 34 Suppl 1: S3-18 [PMID: 18515009 DOI: 10.1016/j.ctrv.2008.03.007]
93. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492 [PMID: 17200148 DOI: 10.1200/jco.2006.08.8617]
94. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369: 559-570 [PMID: 17307102 DOI: 10.1016/s0140-6736(07)60200-1]
95. Coleman RE, Body JJ, Gralow JR, Lipton A. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat Rev 2008; 34 Suppl 1: S31-S42 [PMID: 18486346 DOI: 10.1016/j.ctrv.2008.03.005]
96. National Osteoporosis Foundation (NOF). 2013 Clinician's Guide to Prevention and Treatment of Osteoporosis. Cited 2013-12-02. Available from: URL: http://nof.org/files/nof/public/content/file/950/upload/523.pdf
97. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042-4057 [PMID: 12963702 DOI: 10.1200/jco.2003.08.017]